Who are Chantix's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nicorette, Champix, Evoxac, Provocholine, Salagen, Miochol-E.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/varenicline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Chantix — Competitive Intelligence Brief

Chantix (varenicline) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinergic Receptor Agonist. Area: Neuroscience.

marketed Cholinergic Receptor Agonist Neuronal acetylcholine receptor; alpha4/beta2 Neuroscience Live · refreshed every 30 min

Target snapshot

Chantix (varenicline) — Pfizer. Chantix works by activating the brain's nicotinic receptors, reducing cravings and the pleasurable effects of smoking.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Chantix TARGET	varenicline	Pfizer	marketed	Cholinergic Receptor Agonist	Neuronal acetylcholine receptor; alpha4/beta2	2006-01-01
Nicorette	NICOTINE	Sanofi	marketed	Cholinergic Nicotinic Agonist [EPC]	Neuronal acetylcholine receptor; alpha4/beta2	1991-01-01
Champix	Champix	The Queen Elizabeth Hospital	marketed		Neuronal acetylcholine receptor subunit alpha-7, Neuronal acetylcholine receptor; alpha3/beta4, Neuronal acetylcholine receptor; alpha4/beta2
Evoxac	CEVIMELINE	Cosette	marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M1	2000-01-01
Provocholine	METHACHOLINE	Methapharm	marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M1	1986-01-01
Salagen	PILOCARPINE		marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M4	1974-01-01
Miochol-E	ACETYLCHOLINE		marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M3	1973-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholinergic Receptor Agonist class)

· 2 drugs in this class
Cosette · 1 drug in this class
Methapharm · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Chantix — Competitive Intelligence Brief. https://druglandscape.com/ci/varenicline. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab